Peptide LibraryMaridebart cafraglutide dosage in published studies and labels
These are the doses used for Maridebart cafraglutide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Maridebart cafraglutide (MariTide) has no approved dosage. Human dosing comes from Amgen's phase 2 obesity trial, which gave 140, 280 or 420 mg under the skin every 4 weeks, or 420 mg every 8 weeks, for 52 weeks; mean weight change ranged from -12.3% to -16.2% against -2.5% with placebo in people without diabetes. Phase 3 trials are under way, and their registry entries list low, medium and high doses without amounts.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 140–420 mg every 4 or 8 weeks in the phase 2 trial |
| Route | Subcutaneous |
| Frequency | Every 4 weeks or every 8 weeks |
| Duration studied | 52 weeks in the phase 2 trial; 72 weeks planned in the MARITIME-1 phase 3 trial |
| Titration | Phase 2 compared starting at full dose with 4-week and 12-week dose escalation to 420 mg; gastrointestinal effects were less frequent with escalation and a lower starting dose. |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Phase 2 dose-ranging, obesity cohort (NCT05669599)Clinical trial · Randomized, double-blind, placebo-controlled phase 2 trial | Adults with obesity without type 2 diabetes (n=465) | 140, 280 or 420 mg every 4 weeks, or 420 mg every 8 weeks, with or without dose escalation | Subcutaneous | Every 4 or 8 weeks | 52 weeks | Mean body-weight change at week 52 from -12.3% to -16.2% across groups, against -2.5% with placebo | Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025. |
| Phase 2 dose-ranging, obesity with type 2 diabetes cohort (NCT05669599)Clinical trial · Randomized, double-blind, placebo-controlled phase 2 trial | Adults with obesity and type 2 diabetes (n=127) | 140, 280 or 420 mg, without dose escalation | Subcutaneous | Every 4 weeks | 52 weeks | Mean body-weight change from -8.4% to -12.3% against -1.7% with placebo; HbA1c fell 1.2 to 1.6 percentage points | Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity - A Phase 2 Trial. N Engl J Med. 2025. |
| Phase 1 single and multiple ascending doses (NCT04478708)Clinical trial · Randomized, double-blind, placebo-controlled phase 1 study | Participants with obesity (n not stated in the indexed abstract) | Single and multiple ascending doses; amounts not stated in the indexed abstract | Subcutaneous | Not stated in the indexed abstract | Not stated in the indexed abstract | Dose-dependent weight loss, maintained up to 150 days after the last dose in the multiple-dose cohorts | A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings. Nat Metab. 2024. |
| MARITIME-1 — phase 3, obesity without diabetes (NCT06858839)Clinical trial · Phase 3 randomized, placebo-controlled trial, active not recruiting | Adults with obesity or overweight without type 2 diabetes (n=3,853) | Low, medium or high dose (amounts not given in the registry) | Subcutaneous | Per trial protocol | 72 weeks | Ongoing; no results posted | NCT06858839 — Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight |
Where sources disagree
- Maridebart cafraglutide is an antibody joined to two GLP-1 peptides, so its doses are hundreds of milligrams given monthly or less often. These amounts are not comparable to weekly GLP-1 drugs dosed in single milligrams.
- The phase 3 doses are not public in the registry, which lists only low, medium and high arms. The phase 2 doses may not be the ones finally carried forward.
- It is not FDA-approved.